-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $282

Benzinga·04/15/2026 20:08:03
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $276 to $282.